HEOR / HTA is basically a multidisciplinary policy approach which uses clinical effectiveness, cost-effectiveness, policy and ethical perspectives to provide insights and evidence upon which rational policy decisions on the usage of health technology can be made. HEOR / HTA can be applied for either a single technology (such as a drug or device) or complex interventions (such as rehabilitation). It can be used for individual patient care or public health.

HEOR / Health Technology Assessment HTA is used as a tool to enable the assessment and comparison of health technologies using same metric of cost-effectiveness. Its outcome results in benefit of the patient as well as technology producers because only those technologies which are cost effective are promoted for widespread use.

What would be the job profile of someone graduating from this course?

Academic/research centers or universities – undertake HTA research projects funded by HTA agencies, national research bodies or health technology companies to support reimbursement or develop HTA methods. Private industries including pharmaceutical companies, bio-technology companies and health insurance companies design and undertake evaluations (effectiveness and/or cost-effectiveness) for presentation to reimbursement agencies in support of health technology products. Local or national government agencies, regulators, health service providers and international health organizations (example: WHO) commission and review assessments submitted to support reimbursement of health technologies; undertake systematic reviews, evidence synthesis and evaluations to focus and direct health care policy; evaluate policy and programmes previously funded. National or international consultancy companies undertake HTA projects for governments, HTA agencies or industry clients.

Courses:

Diploma in Health Economics Outcomes Research